Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04686006
Other study ID # KyushuU Iodide 1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 1996

Study information

Verified date December 2020
Source Kyushu University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As the drug treatment of Graves' hyperthyroidism, Plummer reported the effectiveness of excess iodide in 1923 and iodide was used as the therapy for Graves' hyperthyroidism starting from the 1930s. After the introduction of more potent antithyroid drug, thionamide, most thyroidologists preferred to use thionamide expecting potent antithyroid effect, but some careful thyroidologists continued to prescribe iodide in mild type Graves' hyperthyroidism. Recently, American and Europe Thyroid Association recommended methylmercaptoimidazole (MMI), one of the potent thionamide drugs, as the first-choice drug for Graves' hyperthyroidism. However, it became apparent that thionamide has serious side effects such as not only agranulocytosis, but also severe liver injury, MPO-ANCA related vasculitis and embryopathy in the pregnant women. In Japan, one patient died of thionamide-induced agranulocytosis every year. The incidence of side effects including minor side effect of drug eruption is more than 10%. We used to treat the patients with Graves' hyperthyroidism with MMI, as we reported in J Clin Endocrinol Metab 65:719, 1987. However, many side effects of thionamide prompted us to revive the treatment with classical KI in our outpatient clinic and found that KI was effective in the patients who showed side effects to thionamide, resulting in remission (reported in J Clin Endocrinol Metab 99:3995, 2014). Therefore, we began to treat the patients without serious complications such as heart failure or arrhythmia, with 100mg KI since 1996 and followed for 180 days. We were surprised to find that serum thyroid hormone level decreased in all the patients. Thionamide drugs were added only when euthyroidism could not be achieved by KI alone. Compared with thionamide, side effect of KI was almost none. Between 1996 and 2004, about 504 patients were treated with KI and a third of the patients were successfully treated with KI alone and other patients were also successfully treated with the combination of KI and thionamide, suggesting additive effect, or by radioactive iodine therapy. The long term prognosis of the patients initially treated with KI was almost the same as the patients initially treated with MMI. Our clinical experience suggested that patients with Graves' hyperthyroidism are also susceptible to excess iodide, as in the cases with Hashimoto thyroiditis, and this suppressive effect of excess iodide on the thyroid gland is a useful information for many patients suffering from Graves' hyperthyroidism and thionamide side effects.


Recruitment information / eligibility

Status Completed
Enrollment 504
Est. completion date
Est. primary completion date July 1, 2005
Accepts healthy volunteers No
Gender All
Age group 15 Years to 90 Years
Eligibility Inclusion Criteria: Untreated Graves' hyperthyroidism. (elevated serum free T4 and/or free T3 level, suppressed serum TSH level, positive anti-TSH receoptor antibody and high thyroidal radioactive iodine uptake - Exclusion Criteria: dropped out patients within 180 days -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Potassium Iodide


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Kyushu University

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of thyroid function Normalization of serum free T4 level and TSH level during first 180 days on potassium iodide 180 days
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed NCT02973802 - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy Phase 1
Completed NCT02491567 - DNA Methylation and Autoimmune Thyroid Diseases
Terminated NCT01320813 - Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy N/A
Completed NCT00432146 - Effect of Lugol's Solution in the Patients With Graves' Disease N/A
Recruiting NCT06081439 - Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting NCT06327828 - Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Active, not recruiting NCT04135573 - The Relationship Between NK Cell and Graves' Disease
Recruiting NCT06134219 - Course for Brain Fatigue After Graves' Disease Controlled Study N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Completed NCT03009357 - Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Recruiting NCT05510609 - Three-dimensional Ultrasonography Thyroid Volume Measurement. N/A
Not yet recruiting NCT06426758 - Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Recruiting NCT05907668 - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT03303053 - Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Phase 3
Recruiting NCT05461820 - Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease Phase 4